154 related articles for article (PubMed ID: 33566952)
1. Transmission-blocking compound candidates against Plasmodium vivax using P. berghei as an initial screening.
Fabbri C; Trindade AO; Andrade FS; Souza MF; Ríos-Velásquez CM; Lacerda MVG; Monteiro WM; Costa FTM; Amino R; Lopes SCP
Mem Inst Oswaldo Cruz; 2021; 116():e200513. PubMed ID: 33566952
[TBL] [Abstract][Full Text] [Related]
2. Functional Conservation of P48/45 Proteins in the Transmission Stages of
Cao Y; Hart RJ; Bansal GP; Kumar N
mBio; 2018 Sep; 9(5):. PubMed ID: 30181253
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
Bai J; Liu F; Yang F; Zhao Y; Jia X; Thongpoon S; Roobsoog W; Sattabongkot J; Zheng L; Cui Z; Zheng W; Cui L; Cao Y
Vaccine; 2023 Jan; 41(2):555-563. PubMed ID: 36503858
[TBL] [Abstract][Full Text] [Related]
4. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
[TBL] [Abstract][Full Text] [Related]
5. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
Cao Y; Hayashi CTH; Kumar N
J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
[TBL] [Abstract][Full Text] [Related]
7. Similar trends of susceptibility in Anopheles arabiensis and Anopheles pharoensis to Plasmodium vivax infection in Ethiopia.
Abduselam N; Zeynudin A; Berens-Riha N; Seyoum D; Pritsch M; Tibebu H; Eba K; Hoelscher M; Wieser A; Yewhalaw D
Parasit Vectors; 2016 Oct; 9(1):552. PubMed ID: 27756355
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.
Kou X; Zheng W; Du F; Liu F; Wang M; Fan Q; Cui L; Luo E; Cao Y
Parasit Vectors; 2016 Apr; 9():190. PubMed ID: 27038925
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential.
Liu F; Li L; Zheng W; He Y; Wang Y; Zhu X; Tsuboi T; Cui L; Wang M; Cao Y
Infect Immun; 2018 Aug; 86(8):. PubMed ID: 29866905
[TBL] [Abstract][Full Text] [Related]
10. Population dynamics of sporogony for Plasmodium vivax parasites from western Thailand developing within three species of colonized Anopheles mosquitoes.
Zollner GE; Ponsa N; Garman GW; Poudel S; Bell JA; Sattabongkot J; Coleman RE; Vaughan JA
Malar J; 2006 Aug; 5():68. PubMed ID: 16887043
[TBL] [Abstract][Full Text] [Related]
11. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.
de Jong RM; Tebeje SK; Meerstein-Kessel L; Tadesse FG; Jore MM; Stone W; Bousema T
Immunol Rev; 2020 Jan; 293(1):190-215. PubMed ID: 31840844
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
[TBL] [Abstract][Full Text] [Related]
13. Killer yeasts exert anti-plasmodial activities against the malaria parasite Plasmodium berghei in the vector mosquito Anopheles stephensi and in mice.
Cappelli A; Valzano M; Cecarini V; Bozic J; Rossi P; Mensah P; Amantini C; Favia G; Ricci I
Parasit Vectors; 2019 Jul; 12(1):329. PubMed ID: 31266522
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission.
Wang J; Zheng W; Liu F; Wang Y; He Y; Zheng L; Fan Q; Luo E; Cao Y; Cui L
Malar J; 2017 Nov; 16(1):458. PubMed ID: 29132428
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a Membrane Feeding Assay for Plasmodium vivax Infection in Anopheles albimanus.
Vallejo AF; Rubiano K; Amado A; Krystosik AR; Herrera S; Arévalo-Herrera M
PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004807. PubMed ID: 27355210
[TBL] [Abstract][Full Text] [Related]
16. Heparin Administered to
Lantero E; Fernandes J; Aláez-Versón CR; Gomes J; Silveira H; Nogueira F; Fernàndez-Busquets X
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32752200
[TBL] [Abstract][Full Text] [Related]
17. Fueling Open Innovation for Malaria Transmission-Blocking Drugs: Hundreds of Molecules Targeting Early Parasite Mosquito Stages.
Delves M; Lafuente-Monasterio MJ; Upton L; Ruecker A; Leroy D; Gamo FJ; Sinden R
Front Microbiol; 2019; 10():2134. PubMed ID: 31572339
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium vivax gametocytes and transmission.
Bantuchai S; Imad H; Nguitragool W
Parasitol Int; 2022 Apr; 87():102497. PubMed ID: 34748969
[TBL] [Abstract][Full Text] [Related]
19. Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector.
Snewin VA; Premawansa S; Kapilananda GM; Ratnayaka L; Udagama PV; Mattei DM; Khouri E; Del Giudice G; Peiris JS; Mendis KN; David PH
J Exp Med; 1995 Jan; 181(1):357-62. PubMed ID: 7807016
[TBL] [Abstract][Full Text] [Related]
20. Quantitative characterization of hemozoin in Plasmodium berghei and vivax.
Pisciotta JM; Scholl PF; Shuman JL; Shualev V; Sullivan DJ
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):110-119. PubMed ID: 28279945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
